MGO One Seven LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 25.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,610 shares of the medical research company's stock after selling 886 shares during the quarter. MGO One Seven LLC's holdings in Thermo Fisher Scientific were worth $1,358,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pinebridge Investments L.P. lifted its stake in Thermo Fisher Scientific by 26.6% during the fourth quarter. Pinebridge Investments L.P. now owns 125,815 shares of the medical research company's stock worth $65,453,000 after purchasing an additional 26,466 shares in the last quarter. Alta Advisers Ltd lifted its stake in Thermo Fisher Scientific by 26.6% during the fourth quarter. Alta Advisers Ltd now owns 1,266 shares of the medical research company's stock worth $659,000 after purchasing an additional 266 shares in the last quarter. OneDigital Investment Advisors LLC lifted its stake in Thermo Fisher Scientific by 2.0% during the fourth quarter. OneDigital Investment Advisors LLC now owns 13,784 shares of the medical research company's stock worth $7,171,000 after purchasing an additional 268 shares in the last quarter. Van Lanschot Kempen Investment Management N.V. raised its stake in shares of Thermo Fisher Scientific by 43.1% in the fourth quarter. Van Lanschot Kempen Investment Management N.V. now owns 309,975 shares of the medical research company's stock valued at $161,258,000 after acquiring an additional 93,425 shares in the last quarter. Finally, Wealth Dimensions Group Ltd. raised its stake in shares of Thermo Fisher Scientific by 65.1% in the fourth quarter. Wealth Dimensions Group Ltd. now owns 667 shares of the medical research company's stock valued at $347,000 after acquiring an additional 263 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.
Thermo Fisher Scientific Price Performance
Thermo Fisher Scientific stock traded down $8.07 during trading hours on Thursday, hitting $420.93. The stock had a trading volume of 988,404 shares, compared to its average volume of 1,755,508. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The stock has a market capitalization of $158.90 billion, a price-to-earnings ratio of 25.49, a PEG ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific Inc. has a 1-year low of $409.85 and a 1-year high of $627.88. The stock's fifty day moving average is $480.79 and its two-hundred day moving average is $524.13.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Thermo Fisher Scientific's revenue was up .2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.11 earnings per share. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.
Thermo Fisher Scientific Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.
Insider Activity at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 24,200 shares of company stock valued at $13,235,041 over the last quarter. Insiders own 0.33% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on TMO. Evercore ISI reduced their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Raymond James restated an "outperform" rating and issued a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Barclays cut their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price target on the stock in a research note on Friday, January 10th. Finally, Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $607.43.
Read Our Latest Analysis on Thermo Fisher Scientific
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
